DELIVER ON
NATURE’S

POSSIBILITIES
Drag

Our solutions

Non-model industrial strain engineering

Our end-to-end platform, from biological design to scale up to biomanufacturing, delivers industrial solutions with reduced time and risk.

Learn more play--v1

Our solutions

Rapid iterative enzyme engineering

Our end-to-end platform, from biological design to scale up to biomanufacturing, delivers industrial solutions with reduced time and risk.

Learn more play--v1

Our solutions

Immobilized enzyme process development

Our end-to-end platform, from biological design to scale up to biomanufacturing, delivers industrial solutions with reduced time and risk.

Learn more play--v1

Our solutions

Daily life biotech application development

Our end-to-end platform, from biological design to scale up to biomanufacturing, delivers industrial solutions with reduced time and risk.

Learn more play--v1

From lab to pilot and industrial scale

Our 130,000 m(2) industrial manufacturing facility has
an annual production capacity of up to 600 tons, which fulfills the
requirements for large-scale production of bio-food preservatives.

Our pilot plant is equipped with six independent
automated production lines and over 4,000L fermentation capacity.
It allows us to scale up multiple products simultaneously.

From lab to pilot and industrial scale

News
Bota Bio and Medichem Announce Commercial Development Collaboration

SAN FRANCISCO Calif., HANGZHOU, China, and BARCELONA, Spain –August 25, 2022 - Bota Bio and Medichem, a vertically integrated pharmaceutical company engaged in the process development and manufacture of active pharmaceutical ingredients (API) and finished dosage forms (FDF), today announced a commercial development collaboration to increase sustainability while reducing the costs of API manufacturing.

Bota Bio Raises $100 Million Financing led by Sequoia Captical China

SAN FRANCISCO and HANGZHOU, China, July 29, 2021 Bota Bio announced that it has raised more than $100 million in an oversubscribed Series B funding round. The financing was led by Sequoia Capital China. Other investors included previous backers Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital, among others.

Bota Bio LEAP R&D center was inaugurated in Hangzhou, CN

SAN FRANCISCO and HANGZHOU, China, Aug 08, 2023 Bota Bio officially opened the LEAP (Laboratory for Engineering Automation and Process Development) R&D center located in Qiantang Medical Port Town, Hangzhou. It will further empower Bota to accelerate the shifts to biomanufacturing from biological design to scale up for sustainable daily life.

Join Bota

Join us if you want to create sustainable products and solutions.